Filana Therapeutics reports Q2 2026 loss narrows as it works to lift FDA clinical hold on epilepsy drug

Filana Therapeutics reported a net loss of $8.6 million in Q2 2026, significantly lower than the $44.2 million loss in Q2 2025, reflecting reduced R&D and legal expenses. The company is actively addressing the FDA's clinical hold on its simufilam trial for TSC-related epilepsy and engaging with the TSC community at upcoming conferences. Cash reserves stood at $82.7 million as of June 30, 2026, with expectations to maintain $36-$40 million by year-end after a $31.25 million litigation settlement. Progress on regulatory and clinical fronts will be key for future development.